Selected research
Industry Research
Large Molecule Drugs CDMO Industry Research Report 2026
Market perspective
The global Large Molecule Drugs CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Large Molecule Drugs CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Large Molecule Drugs CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Large Molecule Drugs CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Large Molecule Drugs CDMO include Patheon, Eurofins Scientific, Samsung Biologics, Catalent, Inc., Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG and FUJIFILM Diosynth Biotechnologies, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Large Molecule Drugs CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Large Molecule Drugs CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Large Molecule Drugs CDMO Market by Company
Patheon
Eurofins Scientific
Samsung Biologics
Catalent, Inc.
Rentschler Biopharma SE
AGC Biologics
Recipharm AB
Siegfried Holding AG
FUJIFILM Diosynth Biotechnologies
Scorpius
Ardena
Alcami
Cytiva
Thermo Fisher Scientific
Large Molecule Drugs CDMO Segment by Type
Cell Line Development
Large Molecule Drug Substance Development
Large Molecule Drugs CDMO Segment by Application
Biological Technology
Clinical
Pharmaceutical
Others
Large Molecule Drugs CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Large Molecule Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Large Molecule Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Large Molecule Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Large Molecule Drugs CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Line Development
- Large Molecule Drug Substance Development
Applications
- Biological Technology
- Clinical
- Pharmaceutical
- Others
Companies covered
- Patheon
- Eurofins Scientific
- Samsung Biologics
- Catalent, Inc.
- Rentschler Biopharma SE
- AGC Biologics
- Recipharm AB
- Siegfried Holding AG
- FUJIFILM Diosynth Biotechnologies
- Scorpius
- Ardena
- Alcami
- Cytiva
- Thermo Fisher Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Large Molecule Drugs CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cell Line Development
- 2.2.3 Large Molecule Drug Substance Development
- 2.3 Large Molecule Drugs CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biological Technology
- 2.3.3 Clinical
- 2.3.4 Pharmaceutical
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Large Molecule Drugs CDMO Breakdown Data by Type
- 3.1 Global Large Molecule Drugs CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Large Molecule Drugs CDMO Forecasted Market Size by Type (2027-2032)
4 Large Molecule Drugs CDMO Breakdown Data by Application
- 4.1 Global Large Molecule Drugs CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Large Molecule Drugs CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Large Molecule Drugs CDMO Market Perspective (2021-2032)
- 5.2 Global Large Molecule Drugs CDMO Growth Trends by Region
- 5.2.1 Global Large Molecule Drugs CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Large Molecule Drugs CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Large Molecule Drugs CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Large Molecule Drugs CDMO Market Dynamics
- 5.3.1 Large Molecule Drugs CDMO Industry Trends
- 5.3.2 Large Molecule Drugs CDMO Market Drivers
- 5.3.3 Large Molecule Drugs CDMO Market Challenges
- 5.3.4 Large Molecule Drugs CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Large Molecule Drugs CDMO Players by Revenue
- 6.1.1 Global Top Large Molecule Drugs CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Large Molecule Drugs CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Large Molecule Drugs CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Large Molecule Drugs CDMO Head Office and Area Served
- 6.4 Global Large Molecule Drugs CDMO Players, Product Type & Application
- 6.5 Global Large Molecule Drugs CDMO Manufacturers Established Date
- 6.6 Global Large Molecule Drugs CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Large Molecule Drugs CDMO Market Size (2021-2032)
- 7.2 North America Large Molecule Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 7.4 North America Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Large Molecule Drugs CDMO Market Size (2021-2032)
- 8.2 Europe Large Molecule Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 8.4 Europe Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Large Molecule Drugs CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Large Molecule Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Large Molecule Drugs CDMO Market Size (2021-2032)
- 10.2 South America Large Molecule Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 10.4 South America Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Large Molecule Drugs CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Large Molecule Drugs CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Large Molecule Drugs CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Patheon
- 12.1.1 Patheon Company Information
- 12.1.2 Patheon Business Overview
- 12.1.3 Patheon Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.1.4 Patheon Large Molecule Drugs CDMO Product Portfolio
- 12.1.5 Patheon Recent Developments
- 12.2 Eurofins Scientific
- 12.2.1 Eurofins Scientific Company Information
- 12.2.2 Eurofins Scientific Business Overview
- 12.2.3 Eurofins Scientific Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.2.4 Eurofins Scientific Large Molecule Drugs CDMO Product Portfolio
- 12.2.5 Eurofins Scientific Recent Developments
- 12.3 Samsung Biologics
- 12.3.1 Samsung Biologics Company Information
- 12.3.2 Samsung Biologics Business Overview
- 12.3.3 Samsung Biologics Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.3.4 Samsung Biologics Large Molecule Drugs CDMO Product Portfolio
- 12.3.5 Samsung Biologics Recent Developments
- 12.4 Catalent, Inc.
- 12.4.1 Catalent, Inc. Company Information
- 12.4.2 Catalent, Inc. Business Overview
- 12.4.3 Catalent, Inc. Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.4.4 Catalent, Inc. Large Molecule Drugs CDMO Product Portfolio
- 12.4.5 Catalent, Inc. Recent Developments
- 12.5 Rentschler Biopharma SE
- 12.5.1 Rentschler Biopharma SE Company Information
- 12.5.2 Rentschler Biopharma SE Business Overview
- 12.5.3 Rentschler Biopharma SE Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.5.4 Rentschler Biopharma SE Large Molecule Drugs CDMO Product Portfolio
- 12.5.5 Rentschler Biopharma SE Recent Developments
- 12.6 AGC Biologics
- 12.6.1 AGC Biologics Company Information
- 12.6.2 AGC Biologics Business Overview
- 12.6.3 AGC Biologics Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.6.4 AGC Biologics Large Molecule Drugs CDMO Product Portfolio
- 12.6.5 AGC Biologics Recent Developments
- 12.7 Recipharm AB
- 12.7.1 Recipharm AB Company Information
- 12.7.2 Recipharm AB Business Overview
- 12.7.3 Recipharm AB Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.7.4 Recipharm AB Large Molecule Drugs CDMO Product Portfolio
- 12.7.5 Recipharm AB Recent Developments
- 12.8 Siegfried Holding AG
- 12.8.1 Siegfried Holding AG Company Information
- 12.8.2 Siegfried Holding AG Business Overview
- 12.8.3 Siegfried Holding AG Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.8.4 Siegfried Holding AG Large Molecule Drugs CDMO Product Portfolio
- 12.8.5 Siegfried Holding AG Recent Developments
- 12.9 FUJIFILM Diosynth Biotechnologies
- 12.9.1 FUJIFILM Diosynth Biotechnologies Company Information
- 12.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 12.9.3 FUJIFILM Diosynth Biotechnologies Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.9.4 FUJIFILM Diosynth Biotechnologies Large Molecule Drugs CDMO Product Portfolio
- 12.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.10 Scorpius
- 12.10.1 Scorpius Company Information
- 12.10.2 Scorpius Business Overview
- 12.10.3 Scorpius Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.10.4 Scorpius Large Molecule Drugs CDMO Product Portfolio
- 12.10.5 Scorpius Recent Developments
- 12.11 Ardena
- 12.11.1 Ardena Company Information
- 12.11.2 Ardena Business Overview
- 12.11.3 Ardena Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.11.4 Ardena Large Molecule Drugs CDMO Product Portfolio
- 12.11.5 Ardena Recent Developments
- 12.12 Alcami
- 12.12.1 Alcami Company Information
- 12.12.2 Alcami Business Overview
- 12.12.3 Alcami Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.12.4 Alcami Large Molecule Drugs CDMO Product Portfolio
- 12.12.5 Alcami Recent Developments
- 12.13 Cytiva
- 12.13.1 Cytiva Company Information
- 12.13.2 Cytiva Business Overview
- 12.13.3 Cytiva Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.13.4 Cytiva Large Molecule Drugs CDMO Product Portfolio
- 12.13.5 Cytiva Recent Developments
- 12.14 Thermo Fisher Scientific
- 12.14.1 Thermo Fisher Scientific Company Information
- 12.14.2 Thermo Fisher Scientific Business Overview
- 12.14.3 Thermo Fisher Scientific Revenue in Large Molecule Drugs CDMO Business (2021-2026)
- 12.14.4 Thermo Fisher Scientific Large Molecule Drugs CDMO Product Portfolio
- 12.14.5 Thermo Fisher Scientific Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst